Brief: RenovoRx Q3 Net Income USD -2.912 Million
13/11/2025 21:05
Nov 13 (Reuters) - RenovoRx Q3 operating expenses USD 3.413 million. Q3 basic EPS USD -0.08
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies